A Fifty-Two-Week, Multicenter, Open-Label Study Evaluating the Long-Term Safety and Tolerability of Saredutant in Adult and Elderly Patients With Major Depressive Disorder.

Trial Profile

A Fifty-Two-Week, Multicenter, Open-Label Study Evaluating the Long-Term Safety and Tolerability of Saredutant in Adult and Elderly Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Saredutant (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2012 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Actual patient number (365) added as reported by ClinicalTrials.gov.
    • 12 Jun 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top